ライフサイエンスコーパス: nucleoside analog

1 placement reaction provides a functionalized nucleoside analog.

2 pegylated interferon and ribavirin (RBV), a nucleoside analog.

3 .5 determined for tenofovir, another acyclic nucleoside analog.

4 entified by the presence of the incorporated nucleoside analog.

5 py can enhance the efficacy of an anticancer nucleoside analog.

6 explain the biological consequences of this nucleoside analog.

7 iminonucleosides, and C2'- and C4'-modified nucleoside analogs.

8 rstand the efficiency of inhibition for five nucleoside analogs.

9 ntly rests with long-term therapy using oral nucleoside analogs.

10 ns to circumvent the antiviral resistance of nucleoside analogs.

11 mes with new and improved activities towards nucleoside analogs.

12 ons and will suggest future plans with these nucleoside analogs.

13 similar to that reported previously for the nucleoside analogs.

14 tide-mediated excision compared with similar nucleoside analogs.

15 the active metabolite for both these purine nucleoside analogs.

16 s of L-configuration but not D-configuration nucleoside analogs.

17 emic and intracellular levels of anti-cancer nucleoside analogs.

18 tructurally diverse anticancer and antiviral nucleoside analogs.

19 mal residual disease and in combination with nucleoside analogs.

20 these cells to drug-induced apoptosis using nucleoside analogs.

21 of how mutations in RT confer resistance to nucleoside analogs.

22 ns affected the ability of RT to incorporate nucleoside analogs.

23 side effects commonly seen with conventional nucleoside analogs.

24 ncer cells, including the lines resistant to nucleoside analogs.

25 Two pyrimidine nucleoside analogs, [18F]FEAU (1-(2'-deoxy-2'-fluoro-bet

26 The nucleoside analog 2'-C-cyano-2'-deoxy-1-beta-D-arabino-p

27 ucleoside kinase pathway activity, we used a nucleoside analog 2'3'-dideoxycytidine (ddC), which is p

28 The nucleoside analog 2-chloro-2'-deoxyadenosine (CldAdo; cl

29 The archetypical fluorescent nucleoside analog, 2-aminopurine (2Ap), has been used in

30 The pteridine nucleoside analog 3-methyl isoxanthopterin (3-MI) is hig

31 However, the sensitivity of HIV-1 to the nucleoside analog 3TC was not affected by the level of R

32 In contrast, a nucleoside analog (3TC-TP, triphosphate form of lamivudi

33 The nucleoside analog 5-aza-2'-deoxycytidine (5-aza-CdR, dec

34 75 melanoma cells with the DNA demethylating nucleoside analog 5-AZA-2'-deoxycytidine (5-AZA-dC) syne

35 The nucleoside analog 5-azacytidine is an archetypical drug

36 D relies on labeling of nascent DNA with the nucleoside analog 5-ethynyl-2'-deoxyuridine (EdU).

37 ditions in which transport of the pyrimidine nucleoside analog 5-fluorodeoxyuridine (FUdR) would inhi

38 porter Fui1 confers sensitivity to the toxic nucleoside analog 5-fluorouridine.

39 phenotype was confirmed using two additional nucleoside analogs, 5-azacytidine and ribavirin.

40 We introduced the nucleoside analog 8-azanebularine (8-azaN) into this RNA

41 tiviral activities of GS-5734 and the parent nucleoside analog across multiple virus families, provid

42 reby playing a key role in the activity of l-nucleoside analogs against human immunodeficiency virus,

43 tics have also stimulated efforts to develop nucleoside analogs against other positive-strand RNA vir

44 on the safety of long-term therapy with the nucleoside analogs, alone and in combination, are needed

45 delayed chain termination may complement the nucleoside analogs already approved for HIV-1 therapy.

46 c studies reported efficacy with combination nucleoside analog and interferon therapy.

47 was investigated using a series of unnatural nucleoside analogs and a representative PAH diolepoxide,

48 other treatment options: therapy with either nucleoside analogs and alkylator agents, rituximab in co

49 ure of the E. coli enzyme in complex with 10 nucleoside analogs and correlated the structures with ki

50 se that is less important for the binding of nucleoside analogs and deoxynucleoside triphosphates.

51 by combining different drug classes such as nucleoside analogs and HIV protease inhibitors (PIs), ha

52 we investigated the relative potency of the nucleoside analogs and non-nucleoside analogs DHAs on DN

53 We also consider existing nucleoside analogs and novel genomic techniques as poten

54 1) facilitate survival of cells treated with nucleoside analogs and other replication inhibitors.

55 1 protein in cellular response to anticancer nucleoside analogs and precursors, which act without des

56 ents for this patient group, including novel nucleoside analogs and several other agents.

57 gy to increase the antitumor activity of the nucleoside analogs and to overcome tumor cell resistance

58 en treated with alkylating agents and purine nucleoside analogs and would be at higher risk for t-MDS

59 creased the sensitivity of HIV-1 to multiple nucleoside analogs, and a subset of these Q151 variants

60 n of a quasispecies, the choice of mutagenic nucleoside analogs, and the studies that have demonstrat

61 kasugamycin, an aminoglycoside; CGS 15943, a nucleoside analog; and Ro 90-7501, a bibenzimidazole.

62 how that patients treated with commonly used nucleoside analog anti-retroviral drugs progressively ac

63 l-Nucleoside analogs are a new class of clinically active

64 These nucleoside analogs are called "delayed chain terminators

65 Nucleoside analogs are commonly used in the treatment of

66 Several new nucleoside analogs are currently in development for the

67 Several nucleoside analogs are effective in treating leukemias a

68 Many new nucleoside analogs are emerging with novel metabolic pro

69 Nucleoside analogs are frequently used to label newly sy

70 ar determinants of specificity for synthetic nucleoside analogs are not known.

71 Nucleoside analogs are structurally similar antimetaboli

72 Nucleoside analogs are structurally, metabolically, and

73 While nucleoside analogs are used to relieve symptoms of infec

74 eobases, ranging from 5- to 12-membered ring nucleoside analogs, are generated in excellent yield (up

75 some of these goals are being met, and that nucleoside analogs as a class of compounds remain fertil

76 Here, we used genetic and nucleoside analog-based tools to mark and track the orig

77 give slightly improved affinities: bicyclic nucleoside analogs (BCNAs) with a p-alkyl-substituted ph

78 These nucleoside analogs bearing an iodide functional group ha

79 sis, stability and polymerase recognition of nucleoside analogs bearing single bromo- or cyano-deriva

80 es that are activated by clinically relevant nucleoside analogs begins to provide a mechanistic basis

81 lar K(m) value for matched, 3' mispaired, or nucleoside analog beta-l-dioxolane-cytidine terminated n

82 es on HIV reverse transcriptase suggest that nucleoside analogs bind more tightly to the enzyme than

83 apy or in combination with cyclophosphamide, nucleoside analog, bortezomib, or thalidomide-based regi

84 eads to a reduced ability to incorporate the nucleoside analog BrdU, indicating that ASF1 is required

85 immunodeficiency virus (SIV) infection, the nucleoside analog bromodeoxyuridine (BrdU) was administe

86 rmation of the triphosphate metabolites of l-nucleoside analogs (but not d-nucleoside analogs), resul

87 HIV-1 can become resistant to nucleoside analogs by developing an enhanced ability to

88 In contrast, the cytostatic activity of nucleoside analogs carrying a highly toxic purine base a

89 Flow cytometry analyses validate that the nucleoside analog causes apoptosis by blocking cell cycl

90 Clinically, this moderately toxic nucleoside analog causes peripheral neuropathy, hematolo

91 stem cells in the synovium in vivo, a double nucleoside analog cell-labeling scheme was used in a mou

92 that is responsible for the inactivation of nucleoside-analog chemotherapy drugs, in 20/103 (19%) re

93 Although the nucleoside analogs cladribine and pentostatin produce hi

94 We conducted a phase 1 study of a novel nucleoside analog, clofarabine, in pediatric patients wi

95 We assessed the second-generation purine nucleoside analog, clofarabine, in two similar phase II

96 also cross-resistant to cytarabine, another nucleoside analog commonly used in cancer therapy, and 4

97 ding, we developed a "push-pull" fluorescent nucleoside analog composed of dimethylaniline (DMA) fuse

98 e the molecular basis for the development of nucleoside analog compounds with selective activity agai

99 and L21 results in aberrant incorporation of nucleoside analogs, conferring a low fidelity phenotype

100 y double and triple immunostaining to detect nucleoside analogs, conventional MSC markers, and chondr

101 Thus it was postulated that these nucleoside analogs could exert their antiviral effect vi

102 Chain-terminating nucleoside analogs (CTNAs) that cause stalling or premat

103 Chain-terminating nucleoside analogs (CTNAs), which cannot be extended by

104 8-Chloroadenosine (8-Cl-Ado) is a ribosyl nucleoside analog currently in phase I testing for the t

105 e natural nucleotides and the five antiviral nucleoside analogs currently approved for antiviral ther

106 The nucleoside analog cytarabine (Ara-C) is an essential com

107 leukemia (AML) patients and treated with the nucleoside analog DAC induced genome-wide acetylation ch

108 The nucleoside analogs (DAC, 5AC and zebularine) were the mo

109 lated that SAMHD1 sensitizes cancer cells to nucleoside-analog derivatives through the depletion of c

110 phosphorylate both D- and L-nucleosides and nucleoside analogs derives from structural properties of

111 Of potential interest for nucleoside analog development, T. brucei TK was less dis

112 ge, this is the first report to identify the nucleoside analogs DHAs as activators of SIRT6.

113 ve potency of the nucleoside analogs and non-nucleoside analogs DHAs on DNA methylation reversal usin

114 e a rationale against the combination of the nucleoside analogs DHAs with SIRT6 inhibitors or chemoth

115 nt antiretroviral treatment consisted of the nucleoside analog didanosine in the first 43 patients en

116 le for the phosphorylation of all classes of nucleoside analog diphosphates.

117 ed distinction in the metabolism of l- and d-nucleoside analogs, disputing the classic notion that nu

118 fold sensitive to ARC than to the well-known nucleoside analog DRB (5,6-dichloro-1-beta-D-ribofuranos

119 and rCNT2) in their ability to transport the nucleoside analog drug cladribine, 2CdA, (rCNT2 > > > hC

120 harmacological intervention of adenosine and nucleoside analog drug transport by hENT1.

121 port of naturally-occurring nucleosides, and nucleoside analog drugs across the plasma membrane of ep

122 max and K0.5 for substrate at -50 mV for the nucleoside analog drugs gemcitabine (638+/-58 nA, 59.7+/

123 Nucleoside analog drugs that target viral DNA replicatio

124 transports cyclic nucleoside monophosphates, nucleoside analog drugs, chemotherapeutic agents, and pr

125 ter its ability to transport nucleosides and nucleoside analog drugs.

126 the ability of many organisms to incorporate nucleoside analogs during DNA replication, together with

127 een few prospective studies on the safety of nucleoside analogs during pregnancy.

128 the chemoresistance of pancreatic cancer to nucleoside analogs (e.g., gemcitabine).

129 To investigate this, we introduced nucleoside analogs either individually or in tandem into

130 port an asymmetric Pd-catalyzed synthesis of nucleoside analogs enabled by the development of a serie

131 ed and viral DNA levels were quantified from nucleoside analog-experienced children prior to and duri

132 a randomized study of 3 therapy regimens in nucleoside analog-experienced patients.

133 ome inhibitors (bortezomib and carfilzomib), nucleoside analogs (fludarabine and cladribine), and ibr

134 dying the incorporation of alkyne-conjugated nucleoside analogs followed by a fluorescent azide-coupl

135 oteins as well as new progress in the use of nucleoside analogs for inducing lethal mutagenesis have

136 ative and unified structural requirements of nucleoside analogs for interaction with hCNT1, hCNT2, an

137 els in the form of conjugates with activated nucleoside analogs for oral administration in cancer che

138 exible preparation of three classes of these nucleoside analogs from common precursors-properly subst

139 e present a process for rapidly constructing nucleoside analogs from simple achiral materials.

140 Furthermore, as the nucleoside analog ganciclovir is the current drug of cho

141 Resistance to nucleoside analog gemcitabine frequently used in first-l

142 The anticancer nucleoside analog gemcitabine had a reduced affinity for

143 roRNA-21 to be a driver of resistance to the nucleoside analog gemcitabine in human adenocarcinoma ce

144 epleting Mdm4 sensitized p53-/- cells to the nucleoside analog gemcitabine, raising the future perspe

145 All nucleoside analogs have a "Black Box" warning because of

146 Long-term therapy with nucleoside analogs, however, raises a number of practica

147 Targeted screening of nucleoside analogs identified R1479 (4'-azidocytidine) a

148 s and typically conferred resistance to both nucleoside analogs in cell culture.

149 cond, the pseudo-symmetry of nucleosides and nucleoside analogs in combination with their conformatio

150 Synthesis of nucleoside analogs in optically pure form via traditiona

151 We tested a class of nucleoside analogs in which a pseudosugar ring is locked

152 rom Thermus thermophilus HB8 and a series of nucleoside analogs in which the mechanism of discriminat

153 8-Aminoadenosine (8-NH(2)-Ado), a ribosyl nucleoside analog, in preclinical models of multiple mye

154 ere not altered in their susceptibilities to nucleoside analogs; in fact, some of the mutants were hy

155 tential advantages of interferon compared to nucleoside analogs include a lack of drug resistance, a

156 a variety of pyrimidine and acycloguanosine nucleoside analogs, including clinically used antiviral

157 Using a sequential nucleoside analog incorporation assay, we detect a high

158 at signify various stages of the cell cycle: nucleoside-analog incorporation, cell cycle-associated p

159 osure to nucleotide analogues, compared with nucleoside analogs, increased the risk of hip fracture (

160 Mericitabine is a selective nucleoside analog inhibitor of the hepatitis C virus (HC

161 y asking if treatment of woodchucks with the nucleoside analog inhibitor of viral DNA synthesis entec

162 ves of Lys154 were completely resistant to a nucleoside analog inhibitor, 3'-dideoxy 3'-thiacytidine

163 very, from microbial-extract screening, of a nucleoside-analog inhibitor that inhibits bacterial RNA

164 ants exhibited altered susceptibility to the nucleoside analog inhibitors AZT and 3TC.

165 to influence its fidelity and sensitivity to nucleoside analog inhibitors.

166 PPT substrates substituted with a variety of nucleoside analogs [inosine (I), purine riboside (PR), 2

167 In the present study we have used nucleoside analog interference mapping to probe A3G-DNA

168 We have combined nucleoside analog interference with chemical footprintin

169 e long-chain fatty acid amide derivatives of nucleoside analogs into solid lipid nanoparticles may re

170 Monotherapy with interferon or nucleoside analog is generally not recommended during th

171 it is evident that the toxicity of antiviral nucleoside analogs is determined in part by the extent t

172 However, prolonged treatment with nucleoside analogs is often needed to optimize virologic

173 An important mechanism of resistance to nucleoside analogs is the enhanced excision of the analo

174 Acyclovir, a nucleoside analog, is thought to be specific for the hum

175 ions associated with resistance to antiviral nucleoside analogs (K65R, L74V, E89G, Q151N, and M184I)

176 fore and during 30 weeks of therapy with the nucleoside analog L-FMAU [1-(2-fluoro-5-methyl-beta, L-a

177 inofuranoside (Ara-C) treatment and a double nucleoside analog-labeling technique.

178 In this method, a short pulse of nucleoside analog labels replicative regions in the cell

179 2M confers marked hypersusceptibility to the nucleoside analogs lamivudine (3TC) and tenofovir at bot

180 ighlighted in multigram syntheses of d- or l-nucleoside analogs, locked nucleic acids, iminonucleosid

181 Combinations of nucleoside analogs may offer an approach to preventing a

182 activating mutations in NT5C2 and increased nucleoside-analog metabolism in disease progression and

183 h two oxidative traps, a site containing the nucleoside analog methylindole (5'-GMG-3') and a 5'-GGG-

184 Treatment of cells with other nucleoside analogs modified at C-5, 5-fluorodeoxyuridine

185 to measure tumor determinants of response to nucleoside analog (NA) chemotherapy agents such as gemci

186 e often the rate-limiting step in activating nucleoside analog (NA) prodrugs into their cytotoxic, ph

187 Nucleoside analogs (NAs) are considered as appropriate a

188 Nucleoside analogs (NAs) represent an important category

189 Many current antivirals, notably nucleoside analogs (NAs), exert their effect by incorpor

190 ave been approved to treat HIV-1 infections, nucleoside analogs (NRTIs) and nonnucleosides (NNRTIs),

191 se transcriptase (RT): the chain-terminating nucleoside analogs (NRTIs) and the allosteric nonnucleos

192 ylator agents, rituximab in combination with nucleoside analogs, nucleoside analogs plus alkylator ag

193 propyl)adenine (DHPA), a plausibly prebiotic nucleoside analog of adenosine.

194 e methylation machinery in tumor cells using nucleoside analogs of cytosine, such as 5-aza-2'-deoxycy

195 preclinical and clinical findings with other nucleoside analogs or normal deoxynucleotides such as dG

196 y recommended use of single-agent alkylator, nucleoside analog, or standard-dose rituximab therapy.

197 ncorporation of monoclonal antibodies and/or nucleoside analogs, particularly for slow responders or

198 1984, the subsequent introduction of purine nucleoside analogs (pentostatin and cladribine) changed

199 imab in combination with nucleoside analogs, nucleoside analogs plus alkylator agents, or combination

200 Mericitabine is a nucleoside analog polymerase inhibitor of hepatitis C vi

201 Several nucleoside analog prodrugs are dependent on dCK for thei

202 dCK phosphorylates and therefore activates nucleoside analog prodrugs frequently used in cancer, au

203 e activation cascade of medicinally relevant nucleoside analog prodrugs such as AraC, gemcitabine, an

204 c activation of antiviral and antineoplastic nucleoside-analog prodrugs.

205 acetylase inhibitors, monoclonal antibodies, nucleoside analogs, proteasome inhibitors, and signaling

206 Several cytostatic purine nucleoside analogs proved to be susceptible to PNPHyor-m

207 Fluorescent nucleoside analogs provide a means to study DNA interact

208 of the structural basis for activation of L-nucleoside analogs, providing further impetus for discov

209 While the nucleoside analog RBV improves treatment outcome, and wi

210 ith relapsed or primary refractory HCL after nucleoside analogs received rituximab 375 mg/m2 weekly f

211 Nucleoside analogs remain a cornerstone in acute myeloid

212 L-nucleoside analogs represent an important class of small

213 The 2'-C-methyl ribonucleosides are nucleoside analogs representing an important class of an

214 tabolites of l-nucleoside analogs (but not d-nucleoside analogs), resulting in detrimental effects on

215 milar potency as the clinically administered nucleoside analog reverse transcriptase inhibitor azidot

216 azanavir-ritonavir at entry and discontinued nucleoside analog reverse transcriptase inhibitors (NRTI

217 Nucleoside analog reverse transcriptase inhibitors (NRTI

218 ing resistance to protease inhibitors (PIs), nucleoside analog reverse transcriptase inhibitors, and

219 rapy is limited to an off-labeled use of the nucleoside analog ribavirin, which has limited prophylac

220 nt virus was more resistant to the mutagenic nucleoside analogs ribavirin and 5-fluorouracil than the

221 strategy against influenza virus using three nucleoside analogs, ribavirin, 5-azacytidine, and 5-fluo

222 ining tenofovir disoproxil fumarate or other nucleoside analog RT drugs.

223 We found that the replication of nucleoside analog RT inhibitor-, nonnucleoside analog RT

224 was observed between the aptamer and the two nucleoside analog RT inhibitors (azidothymidine triphosp

225 criptase (RT) is selected in vitro by many D-nucleoside analog RT inhibitors (NRTI) but has been rare

226 dine triphosphate or ddCTP), whereas two non-nucleoside analog RT inhibitors showed either weak syner

227 We here show that the nucleoside analog Sangivamycin and its closely-related c

228 Thus, fission yeast responds to nucleoside analogs similarly to mammalian cells, which h

229 T-containing RNA/DNA hybrid are sensitive to nucleoside analog substitution, whereas the intervening

230 f action quite distinct from that of acyclic nucleoside analogs such as acyclovir (ACV) that is based

231 plex virus is a major pathogen, and although nucleoside analogs such as acyclovir are highly effectiv

232 Nucleoside analogs such as BrdU, which are incorporated

233 late certain exogenous substrates, including nucleoside analogs such as ganciclovir.

234 Nucleoside analogs such as gemcitabine diphosphate and c

235 therapies for herpes viral infections employ nucleoside analogs, such as Acyclovir, and target the vi

236 a major target for antiviral drugs including nucleoside analogs, such as the prodrugs mericitabine an

237 Newer more potent nucleoside analogs (tenofovir and entecavir) have proven

238 y a common mechanism, such that incorporated nucleoside analogs terminate chain elongation if the res

239 asia (t-MDS) occurs less frequently with the nucleoside analogs than with DNA-damaging agents such as

240 ldAdo thus represents the first example of a nucleoside analog that acts as a transcriptional antagon

241 FLT is a nucleoside analog that enters cells and is phosphorylate

242 infectivity can be decreased by combining a nucleoside analog that forms noncanonical base pairs wit

243 Importantly, remdesivir, a broad-spectrum nucleoside analog that is effective against other group

244 d favorably with fludarabine, another purine nucleoside analog that is more commonly used in the trea

245 5-Azacytidine (AZA) is a nucleoside analog that is used to treat preleukemic and

246 The antiviral drug acyclovir is a guanosine nucleoside analog that potently inhibits herpes simplex

247 ethynyl-2-fluoro-2'-deoxyadenosine (EFdA), a nucleoside analog that retains a 3'-hydroxyl moiety, inh

248 4 is a monophosphate prodrug of an adenosine nucleoside analog that showed therapeutic efficacy in a

249 not suitable for development as drugs, other nucleoside analogs that cause delayed chain termination

250 We have describe nucleoside analogs that do not block DNA synthesis at th

251 We have developed nucleoside analogs that do not block DNA synthesis at th

252 dentify a promising strategy to design novel nucleoside analogs that exert profound antiviral activit

253 Achieving a similar phenotype with nucleoside analogs that have different effects on duplex

254 d therapeutics are largely based on modified nucleoside analogs that inhibit viral DNA polymerase fun

255 ted in the complementation assay to identify nucleoside analogs that mimic this base-mispairing and p

256 Many antiviral and anticancer drugs are nucleoside analogs that target polymerases and cause DNA

257 complicated by the dual activity of several nucleoside analogs, the more rapid development of lamivu

258 x, histone deacetylase inhibitors, and novel nucleoside analog therapies, have demonstrated promising

259 duction in PSCs may increase the efficacy of nucleoside analog therapies.

260 ic activity and resistance to treatment with nucleoside analog therapies.

261 tegies to improve on the initial response to nucleoside analog therapy are likely to be beneficial, a

262 as been shown to be effective, and long-term nucleoside analog therapy has been demonstrated to maint

263 Although antiviral nucleoside analog therapy successfully delays progressio

264 monotherapy) to 12.4% during 1997-1999 (dual-nucleoside analog therapy) and 14.3% during 2005-2009 (r

265 r a finite course of pegylated interferon or nucleoside analog therapy, with possible long-term maint

266 of conventional alfa interferon to a year of nucleoside analog therapy.

267 e more activated, which can be normalized by nucleoside analog therapy.

268 s B immunoglobulin and treatment with potent nucleoside analogs, there has been a resurgence of LT fo

269 trated effectiveness in sensitizing cells to nucleoside analogs, thus offering a means to elude drug

270 or parasite and LRV1 inhibition, focusing on nucleoside analogs to capitalize on the highly active sa

271 We have examined other nucleoside analogs to determine whether these compounds

272 hat the enzyme can selectively phosphorylate nucleoside analogs to produce products toxic to the cell

273 of reducing N-hydroxylated base analogs and nucleoside analogs to the corresponding canonical nucleo

274 lidated in the clinic, the prospect of using nucleoside analogs to treat acute infections caused by R

275 ances the ability of entecavir, an antiviral nucleoside analog, to reduce viral DNA production in HBV

276 previously described the identification of a nucleoside analog transcriptional inhibitor ARC (4-amino

277 Previously, we identified a novel nucleoside analog transcriptional inhibitor ARC (4-amino

278 y thereafter, the introduction of the purine nucleoside analogs transformed this disease into a highl

279 to their DNA synthesis-directed actions many nucleoside analogs trigger apoptosis by unique mechanism

280 o almost all drugs, including gemcitabine, a nucleoside analog used as a first-line treatment.

281 MB-231 breast cancer cells to gemcitabine, a nucleoside analog used in chemotherapy for triple-negati

282 Gemcitabine (GMT) is a nucleoside analog used in the treatment of a variety of

283 ide (cytarabine, ara-C) represent a class of nucleoside analogs used in cancer chemotherapy.

284 take of natural nucleosides and a variety of nucleoside analogs used in the chemotherapy of cancer an

285 the safety profile of the five approved oral nucleoside analogs used to treat chronic hepatitis B vir

286 n wild-type enzyme and a mutant resistant to nucleoside analogs used to treat HIV infections reveal t

287 ondria related to aging and as compounded by nucleoside analogs used to treat human immunodeficiency

288 a glycolytic enzyme, in the metabolism of l-nucleoside analogs, using small interfering RNAs to down

289 Recent experiments with mutagenic nucleoside analogs validate this new approach to treatin

290 he uptake and disposition of clinically used nucleoside analogs, we determined the haplotype structur

291 Regimens that included rituximab and a nucleoside analog were associated with superior rates of

292 The desired 5'-O-DMT-protected nucleoside analogs were synthesized from suitably protec

293 Sapacitabine is an oral deoxycytidine nucleoside analog with a unique mechanism of action that

294 binofuranosyladenine) is a second-generation nucleoside analog with activity in acute leukemias.

295 Entecavir is a nucleoside analog with potent antiviral efficacy, and in

296 s compound, 6-ethylthioinosine (6-ETI), is a nucleoside analog with toxicity to PEL in vitro and in v

297 Troxacitabine is a non-natural nucleoside analog with unique structural and metabolic f

298 s, we identified chimeras that phosphorylate nucleoside analogs with higher activity than either pare

299 nalysis of the inward currents induced by 27 nucleoside analogs with substitutions at both the ribose

300 xcision pathway to develop resistance to the nucleoside analog zidovudine (AZT), HIV-2 RT does not ap